Rangering i aksjer
#18604
Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in... Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.
Aksjekurs
$0.88044964
Sist synkronisert: 2026-07-31
Handel Circio Holding ASA (CRNA)
Pris CRNA pris med markedsverdi på B
Markedsverdi av Circio Holding ASA(CRNA)
Markedsverdi: $192.54M
Per August 2026 har Circio Holding ASA en markedsverdi på $192.54M. Dette gjør Circio Holding ASA til det 18604th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Circio Holding ASA fra 2016 til 2026
CRNA sammenlignet med topp 5 mest populære stocks
| Pris på CRNA |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.088T
|
+2,642,458.94%
|
|
|
|
|
$4.629T
|
+2,404,177.67%
|
|
|
|
|
$4.108T
|
+2,133,786.54%
|
|
|
|
|
$3.687T
|
+1,914,721.92%
|
|
|
|
|
$2.800T
|
+1,453,992.01%
|
